This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Immunomedics Up as Breast Cancer Drug Study Shows Efficacy
by Zacks Equity Research
Immunomedics (IMMU) soars as the phase III study on breast cancer drug shows efficacy and will be subsequently halted.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Merck & Co, Novartis, PayPal and IBM
Bristol Myers/Acceleron's Reblozyl Label Expansion Gets FDA Nod
by Zacks Equity Research
Bristol Myers (BMY) and Acceleron received FDA nod for the label expansion of Reblozyl for MDS patients who require RBC transfusions, failing an erythropoiesis stimulating agent.
Top Stock Reports for J&J, Merck, Novartis & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Merck (MRK) and Novartis (NVS).
Pharma Coronavirus Efforts Continue, Amgen & Incyte Join In
by Kinjel Shah
Amgen (AMGN) signs a deal with Adaptive Biotechnologies to discover antibodies to prevent/treat COVID-19. Incyte/Novartis (NVS) plan to initiate study on Jakafi for COVID-19- associated cytokine storm.
Novartis Terminates Sale of Sandoz Dermatology Business
by Zacks Equity Research
Novartis (NVS) terminates sale of Sandoz US generic oral solids and dermatology businesses to Aurobindo Pharma USA Inc.
NVS vs. NVO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
NVS vs. NVO: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Novartis, Teva, Gilead and AbbVie
Lilly's Taltz Gets FDA Nod for Plaque Psoriasis in Children
by Zacks Equity Research
The FDA approves Eli Lilly's (LLY) sBLA for Taltz injection to treat pediatric patients with moderate to severe plaque psoriasis. Stock up.
COVID-19 Claiming Lives But Therapeutics Could Be on the Way
by Sejuti Banerjea
The WHO's Solidarity testing project could be good news for the world.
Novartis Reports Data on Inclisiran, CHMP Positive on Zolgensma
by Zacks Equity Research
Novartis (NVS) announces pipeline updates on inclisiran and regulatory updates on Cosentyx and Zolgensma.
Jazz's (JAZZ) Xyrem Follow-On Candidate NDA Gets FDA Acceptance
by Zacks Equity Research
The FDA accepts Jazz's (JAZZ) regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem in the United States.
Novartis to Donate Generic Hydroxychloroquine for Coronavirus
by Zacks Equity Research
Novartis (NVS) will donate 130 million doses of generic hydroxychloroquine for COVID-19 treatment.
Aduro's (ADRO) Earnings & Revenues Miss Estimates in Q4
by Zacks Equity Research
Aduro (ADRO) incurs wider-than-expected loss in Q4. Revenues too fall short of the mark.
Puma Biotech's (PBYI) Nerlynx Aids Growth Despite Competition
by Zacks Equity Research
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. High dependence on Nerlynx for growth remains a woe.
AMAG Sees High Feraheme Sales, To Sell Women Healthcare Drugs
by Zacks Equity Research
AMAG (AMAG) plans to divest two of its women healthcare drugs, Intrarosa and Vyleesi. Its marketed drug, Feraheme, achieves record sales in 2019.
J&J Files MAA for Multiple Sclerosis Drug Ponesimod in Europe
by Zacks Equity Research
Ponesimod's regulatory application in Europe is based on data from the head-to-head OPTIMUM phase III study comparing it to Sanofi's (SNY) MS drug, Aubagio
Alnylam's Givlaari Gets Approval in Europe for Rare Disease
by Zacks Equity Research
Alnylam's (ALNY) second RNAi-based therapeutics, Givlaari receives approval in Europe for treating acute hepatic porphyria, becoming the first and only approved therapy for the indication.
The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Novartis, Mondelez International, ServiceNow and General Dynamics
Roche's Esbriet Gets FDA Breakthrough Tag for New Indication
by Zacks Equity Research
Roche (RHHBY) gets Breakthrough Therapy status from the FDA for Esbriet in adults with unclassifiable interstitial lung disease.
Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B
by Zacks Equity Research
Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.
Top Analyst Reports for Merck, Novartis & Mondelez
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Novartis (NVS) and Mondelez International (MDLZ).
Pharma Stock Roundup: FDA Updates From LLY, GSK, NVS, SNY to Spin-Off API Unit
by Kinjel Shah
FDA accepts Glaxo (GSK) and Novartis' (NVS) sBLA. FDA gives approval to Lilly's (LLY) Trulicity for cardiovascular indication.
United Therapeutics (UTHR) Down on Q4 Earnings & Sales Miss
by Zacks Equity Research
United Therapeutics (UTHR) misses fourth-quarter estimates on both fronts. Stock declines in response.
Bayer (BAYRY) Q4 Earnings Beat Estimates, Sales Rise Y/Y
by Zacks Equity Research
Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2019.